Viewing StudyNCT00154388



Ignite Creation Date: 2024-05-05 @ 11:52 AM
Last Modification Date: 2024-10-26 @ 9:15 AM
Study NCT ID: NCT00154388
Status: COMPLETED
Last Update Posted: 2016-11-18
First Post: 2005-09-09

Brief Title: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Conditions & Keywords Data

Conditions:
Name
Life Threatening Diseases
Keywords:
Name View
adenocarcinoma View
leiomyosarcoma View
angiosarcoma View
synovial sarcoma View
myelodysplastic syndromeHES View
CMML View
multiple myeloma View
embryonal rhabdomyosarcoma View
endometrial sarcoma View
adenoid cystic carcinoma View
fibromatosis View
ductal invasive breast carcinoma View
chondrosarcoma View
pleural tumor View
brenner tumor View
ewing sarcoma View
round cell tumor View
seminoma View
thymic carcinoma View
malignant melanoma View
fibrosarcoma breast View
dermatofibrosarcoma protuberans View
DFSP View
ovarian stromal tumor View
osteosarcoma View
chorioideal melanoma View
hemangiopericytoma View
myelofibrosis View
liposarcoma View
SCLC View
small cell lung carcinoma View
hypereosinophilic syndrome View
chronic myelo-monocytic leukemia View
neurofibrosarcoma View
mesothelioma View
malignant mesenchymoma View
malignant schwannoma View
mast cell leukemia mastocytosis View
renal cell carcinoma View
malignant histocytoma View
chordoma View